Dragoni G - Search Results

1

Understanding fatigue in primary biliary cholangitis: From pathophysiology to treatment perspectives.

Lynch EN, Campani C, Innocenti T, Dragoni G, Biagini MR, Forte P, Galli A. Lynch EN, et al. Among authors: dragoni g. World J Hepatol. 2022 Jun 27;14(6):1111-1119. doi: 10.4254/wjh.v14.i6.1111. World J Hepatol. 2022. PMID: 35978669 Free PMC article. Review.

2

Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.

Dragoni G, Bagnoli S, Le Grazie M, Campani C, Rogai F, Manetti N, Bensi C, Macrì G, Galli A, Milla M. Dragoni G, et al. J Dig Dis. 2019 May;20(5):235-242. doi: 10.1111/1751-2980.12748. J Dig Dis. 2019. PMID: 30927309

3

Non-small-bowel lesions identification by capsule endoscopy: A single centre retrospective study.

Innocenti T, Dragoni G, Roselli J, Macrì G, Mello T, Milani S, Galli A. Innocenti T, et al. Among authors: dragoni g. Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101409. doi: 10.1016/j.clinre.2020.03.011. Epub 2020 Mar 31. Clin Res Hepatol Gastroenterol. 2021. PMID: 32245690

4

CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib.

Colagrande S, Calistri L, Campani C, Dragoni G, Lorini C, Nardi C, Castellani A, Marra F. Colagrande S, et al. Among authors: dragoni g. Eur Radiol. 2021 Mar;31(3):1608-1619. doi: 10.1007/s00330-020-07171-3. Epub 2020 Aug 22. Eur Radiol. 2021. PMID: 32827266 Free PMC article.

5

Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?

Dragoni G, Innocenti T, Galli A. Dragoni G, et al. Dig Dis. 2021;39(3):190-203. doi: 10.1159/000511641. Epub 2020 Sep 17. Dig Dis. 2021. PMID: 32942275 Free article.

6

Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib.

Colagrande S, Calistri L, Campani C, Dragoni G, Lorini C, Nardi C, Castellani A, Marra F. Colagrande S, et al. Among authors: dragoni g. Eur Radiol. 2021 Jun;31(6):4409. doi: 10.1007/s00330-020-07592-0. Eur Radiol. 2021. PMID: 33320291 Free PMC article. No abstract available.

7

Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study.

Grazie ML, Bagnoli S, Dragoni G, Caini S, Annese V, Innocenti T, Deiana S, Manetti N, Milani S, Galli A, Milla M. Grazie ML, et al. Among authors: dragoni g. Ann Gastroenterol. 2021;34(3):370-377. doi: 10.20524/aog.2021.0584. Epub 2021 Jan 27. Ann Gastroenterol. 2021. PMID: 33948062 Free PMC article.

8

Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

Campani C, Vitale A, Dragoni G, Arena U, Laffi G, Cillo U, Giannini EG, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F, Marra F. Campani C, et al. Among authors: dragoni g. Liver Cancer. 2021 Apr;10(2):126-136. doi: 10.1159/000513404. Epub 2021 Mar 17. Liver Cancer. 2021. PMID: 33977089 Free PMC article.

9

Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment.

Cucchetti A, Gramenzi A, Johnson P, Giannini EG, Tovoli F, Rapaccini GL, Marra F, Cabibbo G, Caturelli E, Gasbarrini A, Svegliati-Baroni G, Sacco R, Zoli M, Morisco F, Di Marco M, Mega A, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Cucchetti A, et al. Eur J Cancer. 2021 Oct 16;158:133-143. doi: 10.1016/j.ejca.2021.09.018. Online ahead of print. Eur J Cancer. 2021. PMID: 34666215

10

Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.

Innocenti T, Roselli J, Lynch EN, Apolito P, Parisio L, Bagnoli S, Macrì G, Rogai F, Tarocchi M, Milani S, Galli A, Milla M, Dragoni G. Innocenti T, et al. Among authors: dragoni g. Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e574-e579. doi: 10.1097/MEG.0000000000002166. Eur J Gastroenterol Hepatol. 2021. PMID: 35048649

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters